Shares of medical device company Globus Medical (NYSE:GMED) fell 11.6% in the afternoon session after the company reported third-quarter 2026 revenue below Wall Street's estimates and lowered its full-year revenue guidance.
Globus Medical (NYSE:GMED) has agreed to acquire Synaptive Medical to expand its cranial neurosurgery technology portfolio. The transaction adds Synaptive's visualization, navigation, and surgical planning platforms to Globus Medical's existing spine and robotics offerings. The Synaptive Medical acquisition, which targets complex cranial procedures, could reshape how investors think about Globus Medical's future mix of technologies. Check out 5 other big wins that Globus Medical investors...
On Thursday, Globus Medical (NYSE:GMED) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial
Globus Medical recently reported that it is gaining market share in musculoskeletal solutions, supported by over 60 active product development projects and several new launches across implantable devices, biologics, accessories, and surgical instruments. The company’s debt-free balance sheet and substantial cash reserves are enabling continued investment in R&D, sales infrastructure, and manufacturing expansion, strengthening its position in this specialized segment. Next, we’ll examine how...
Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.
GMED gains musculoskeletal share on strong spine and trauma growth, while product innovation and a debt-free balance sheet support its appeal.
Detailed price information for Intuitive Surg Inc (ISRG-Q) from The Globe and Mail including charting and trades.
Globus Medical (GMED) has drawn investor attention after recent price moves left the stock down about 10% over the past month and roughly 5% lower over the past 3 months. Set against that short term pullback, Globus Medical’s 1 year total shareholder return of 32.5% and 3 year total shareholder return of 50.8% point to a very different picture from the recent 1 month share price decline of about 9.9% and 3 month share price drop of roughly 5.4%. This signals that momentum has cooled recently...
Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.
Globus Medical (GMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Veracyte, Globus Medical and UFP Technologies are positioned to benefit as GenAI adoption reshapes medical instruments.
Globus Medical, NetApp and Assurant stand out for strong projected sales growth as investors navigate renewed Middle East tensions.
Globus Medical (NYSE:GMED) announced that its Excelsius3D imaging system has received CE marking for use in the European Union and United Kingdom. The approval allows Globus Medical to begin commercial launch of the Excelsius3D system across these markets. Excelsius3D is part of Globus Medical's broader imaging and navigation platform for spine and orthopedic procedures. For readers interested in more ways to get exposure to surgical imaging, guidance and automation trends, explore 36...
The Excelsius3D system is a mobile imaging platform combining 3D CT, 2D fluoroscopy, and digital radiography.
This is the newest page. Registered accounts read further back.